| abstract |
This invention describes (20S) 1a-hydroxy-2a-methyl-19-nor-vitamin D3 and (20S) 1a-hydroxy-2b-methyl-19-nor-vitamin D3 and its pharmaceutical uses. These compounds exhibit pronounced activity to curb the proliferation of non-differentiated cells and induce their differentiation to monocyte in this way evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions. such as wrinkles, loose skin, dry skin and insufficient sebum secretion. These compounds also have very significant calcemic activity and therefore can be used to treat immune disorders in humans as well as bone metabolic diseases such as osteoporosis. |